Title: Intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid.
Authors: Witte, M.; Zillikens, D.; Shimanovich, I.
Abstract: The article presents a study focusing on intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid (MMP). Topics include rituximab (anti-CD20) and high-dose intravenous immunoglobulins (IVIG) both have been reported to be effective in refractory MMP and the clinical improvement in patients was due to a delayed response to rituximab or the combination of rituximab and IVIG.
Subjects: MUCOUS membrane diseases; INTRAVENOUS immunoglobulins; THERAPEUTIC use of immunoglobulins; RITUXIMAB; PATIENTS
Publication: Journal of the European Academy of Dermatology & Venereology, 2018, Vol 32, Issue 8, pe321
ISSN: 0926-9959
Publication type: Academic Journal
DOI: 10.1111/jdv.14873

Intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid.

Witte, M.; Zillikens, D.; Shimanovich, I.